# Corliber

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/corliber

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Total disclosed funding: $7.8M
- Latest round: Series A (Jun 17, 2021)
- Investors on record: 1

## About

Established in 2016 and based in Guangdong, China, Corliber is a biotechnology company engaged in the development of new biomedical materials and orthopedic implanted medical devices. The founder graduated from the National University of Singapore with a Ph.D. in medical field. 

Corliber researches and develops high-purity lactide monomer preparation technology, high-purity ultra-high molecular weight medical grade polylactic acid (PLA) synthesis technology and other composite medical raw material preparation technology. The company has patents for materials such as hydroxyapatite (HA) core-shell structure modification and nano-level HA dispersion composite materials. 

In the future, Corliber will continue to advance new pipelines such as Corliber Oral Artificial Bone and suspension plates, metal anchors, and fillable and biodegradable medical beauty products. In terms of new product development, the company plans to accelerate the progress of obtaining evidence for artificial bone and absorbable interface screws, and actively engage in more academic research and develop market-oriented sales channels.

## Funding rounds

- Series A, Jun 17, 2021, $7.8M — Cenova Ventures

## Investors

- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series A